[CAS NO. 19388-87-5] Taurolidine

Name: Taurolidine
Brand: Arctom Scientific
SKU: HY-W011522

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [19388-87-5]

Distributor

Catalog

HY-W011522

Brand

MCE

CAS

19388-87-5

DESCRIPTION [19388-87-5]

Overview

MDL	MFCD00865076
Molecular Weight	284.35
Molecular Formula	C7H16N4O4S2
SMILES	O=S1(NCN(CN(CC2)CNS2(=O)=O)CC1)=O

For research use only. We do not sell to patients.

Summary

Taurolidine is a broad-spectrum antimicrobial for the prevention of central venous catheter-related infections. Taurolidine has a direct and selective antineoplastic effect on brain tumor cells by the induction of apoptosis ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02515201	Hospital de Clinicas de Porto Alegre	Catheter-Related Infections	September 2014	Phase 4
NCT00749619	Western Galilee Hospital-Nahariya	End Stage Renal Disease\|Hemodialysis	May 2007	Phase 3
NCT02036255	Universitair Ziekenhuis Brussel	Patency\|Infection	May 2015	Phase 3
NCT00022360	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors	May 2001	Phase 1
NCT00021034	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Fallopian Tube Cancer\|Ovarian Cancer\|Primary Peritoneal Cavity Cancer	March 2001	Phase 1
NCT00545831	University Hospital, Rouen	Sepsis	October 2007	Not Applicable
NCT01243710	Imperial College Healthcare NHS Trust	Renal Dialysis\|Catheter-Related Infections	August 2010	Phase 4
NCT02009189	Stanley Dudrick´s Memorial Hospital	Home Parenteral Nutrition\|Central Venous Catheter	November 2012	Phase 4
NCT00321165	Radboud University Medical Center	Parenteral Nutrition\|Infection\|Sepsis	June 2006	Phase 3
NCT03539718	Ain Shams University	Hemodialysis Catheter Infection\|Thrombosis; Dialysis Catheter	May 15, 2018	Phase 4
NCT05576194	Stefan Borov\|University of Luebeck\|University of Kiel	Cardiac Implantable Electronic Device Infection	January 1, 2020

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL ( 219.80 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5168 mL	17.5840 mL	35.1679 mL
5 mM	0.7034 mL	3.5168 mL	7.0336 mL
10 mM	0.3517 mL	1.7584 mL	3.5168 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (7.31 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (7.31 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (7.31 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2H-1,2,4-Thiadiazine, 4,4′-methylenebis[tetrahydro-, 1,1,1′,1′-tetraoxide

Taurolin

4,4′-Methylenebis(perhydro-1,2,4-thiadiazin 1,1-dioxide)

Tauroline

Taurolidine

T 7329